These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38086239)

  • 21. Novel hematopoietic progenitor kinase 1 inhibitor KHK-6 enhances T-cell activation.
    Ahn MJ; Kim EH; Choi Y; Chae CH; Kim P; Kim SH
    PLoS One; 2024; 19(6):e0305261. PubMed ID: 38923962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological evaluation of 2,4-diaminopyrimidine derivatives as potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors.
    Fu S; Wei J; Li C; Zhang N; Yue H; Yang A; Xu J; Dong K; Xing Y; Tong M; Shi X; Xi Z; Wang H; Hou Y; Zhao Y
    Bioorg Chem; 2024 Jul; 148():107454. PubMed ID: 38795581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
    Sinatra L; Yang J; Schliehe-Diecks J; Dienstbier N; Vogt M; Gebing P; Bachmann LM; Sönnichsen M; Lenz T; Stühler K; Schöler A; Borkhardt A; Bhatia S; Hansen FK
    J Med Chem; 2022 Dec; 65(24):16860-16878. PubMed ID: 36473103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of hematopoietic progenitor kinase 1 involves relocation, autophosphorylation, and transphosphorylation by protein kinase D1.
    Arnold R; Patzak IM; Neuhaus B; Vancauwenbergh S; Veillette A; Van Lint J; Kiefer F
    Mol Cell Biol; 2005 Mar; 25(6):2364-83. PubMed ID: 15743830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody.
    Zeng S; Wu M; Jin Y; Ye Y; Xia H; Chen X; Che J; Wang Z; Wu Y; Dong X; Chen Y; Huang W
    Eur J Med Chem; 2024 Mar; 267():116206. PubMed ID: 38350360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of Macrocycle-Based HPK1 Inhibitors for T-Cell-Based Immunotherapy.
    Wang MS; Wang ZZ; Li ZL; Gong Y; Duan CX; Cheng QH; Huang W; Yang GF
    J Med Chem; 2023 Jan; 66(1):611-626. PubMed ID: 36542759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Down-regulation of B cell receptor signaling by hematopoietic progenitor kinase 1 (HPK1)-mediated phosphorylation and ubiquitination of activated B cell linker protein (BLNK).
    Wang X; Li JP; Kuo HK; Chiu LL; Dement GA; Lan JL; Chen DY; Yang CY; Hu H; Tan TH
    J Biol Chem; 2012 Mar; 287(14):11037-48. PubMed ID: 22334673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies.
    Si J; Shi X; Sun S; Zou B; Li Y; An D; Lin X; Gao Y; Long F; Pang B; Liu X; Liu T; Chi W; Chen L; Dimitrov DS; Sun Y; Du X; Yin W; Gao G; Min J; Wei L; Liao X
    Cancer Cell; 2020 Oct; 38(4):551-566.e11. PubMed ID: 32860752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of quinazoline HPK1 inhibitors with high cellular potency.
    Toure M; Johnson T; Li B; Schmidt R; Ma H; Neagu C; Lopez AU; Wang Y; Guler S; Xiao Y; Henkes R; Ho K; Zhang S; Chu CL; Gundra UM; Porichis F; Li L; Maurer CK; Fang Z; Musil D; DiPoto M; Friis E; Jones R; Jones C; Cummings J; Chekler E; Tanzer EM; Huck B; Sherer B
    Bioorg Med Chem; 2023 Sep; 92():117423. PubMed ID: 37531921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of pan-IAP degraders via a CRBN recruiting mechanism.
    Park S; Kim D; Lee W; Cho JH; Kim S; Lee GS; Moon JH; Kim JA; Ha JD; Kim JH; Kim HJ
    Eur J Med Chem; 2023 Jan; 245(Pt 2):114910. PubMed ID: 36410083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer.
    Yu X; Li D; Kottur J; Kim HS; Herring LE; Yu Y; Xie L; Hu X; Chen X; Cai L; Liu J; Aggarwal AK; Wang GG; Jin J
    J Med Chem; 2023 Dec; 66(23):16168-16186. PubMed ID: 38019706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MAP4K Family Kinases in Immunity and Inflammation.
    Chuang HC; Wang X; Tan TH
    Adv Immunol; 2016; 129():277-314. PubMed ID: 26791862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of an Allosteric, Inactive Conformation-Selective Inhibitor of Full-Length HPK1 Utilizing a Kinase Cascade Assay.
    Wang W; Mevellec L; Liu A; Struble G; Miller R; Allen SJ; Federowicz K; Wroblowski B; Vialard J; Ahn K; Krosky D
    Biochemistry; 2021 Oct; 60(41):3114-3124. PubMed ID: 34608799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1.
    Hu M; Zhou W; Wang Y; Yao D; Ye T; Yao Y; Chen B; Liu G; Yang X; Wang W; Xie Y
    Acta Pharm Sin B; 2020 Oct; 10(10):1943-1953. PubMed ID: 33163345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function.
    Hernandez S; Qing J; Thibodeau RH; Du X; Park S; Lee HM; Xu M; Oh S; Navarro A; Roose-Girma M; Newman RJ; Warming S; Nannini M; Sampath D; Kim JM; Grogan JL; Mellman I
    Cell Rep; 2018 Oct; 25(1):80-94. PubMed ID: 30282040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of potent and selective HPK1 inhibitors based on the 2,4-disubstituted pyrimidine scaffold with immune modulatory properties for ameliorating T cell exhaustion.
    Zeng S; Zeng M; Yuan S; He L; Jin Y; Huang J; Zhang M; Yang M; Pan Y; Wang Z; Chen Y; Xu X; Huang W
    Bioorg Chem; 2023 Oct; 139():106728. PubMed ID: 37536217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy.
    Malchow S; Korepanova A; Panchal SC; McClure RA; Longenecker KL; Qiu W; Zhao H; Cheng M; Guo J; Klinge KL; Trusk P; Pratt SD; Li T; Kurnick MD; Duan L; Shoemaker AR; Gopalakrishnan SM; Warder SE; Shotwell JB; Lai A; Sun C; Osuma AT; Pappano WN
    ACS Chem Biol; 2022 Mar; 17(3):556-566. PubMed ID: 35188729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, and biological evaluation of Wee1 kinase degraders.
    Zhu S; Liu J; Xiao D; Wang P; Ma J; Hu X; Fu J; Zhou Y; Li J; Lu W
    Eur J Med Chem; 2022 Dec; 243():114786. PubMed ID: 36170799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple conformational states of the HPK1 kinase domain in complex with sunitinib reveal the structural changes accompanying HPK1 trans-regulation.
    Johnson E; McTigue M; Gallego RA; Johnson TW; Timofeevski S; Maestre M; Fisher TS; Kania R; Sawasdikosol S; Burakoff S; Cronin CN
    J Biol Chem; 2019 Jun; 294(23):9029-9036. PubMed ID: 31018963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leukocyte-specific adaptor protein Grap2 interacts with hematopoietic progenitor kinase 1 (HPK1) to activate JNK signaling pathway in T lymphocytes.
    Ma W; Xia C; Ling P; Qiu M; Luo Y; Tan TH; Liu M
    Oncogene; 2001 Mar; 20(14):1703-14. PubMed ID: 11313918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.